Sagespring Wealth Partners LLC Has $8.81 Million Holdings in AbbVie Inc. $ABBV

Sagespring Wealth Partners LLC lifted its position in AbbVie Inc. (NYSE:ABBV) by 12.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,051 shares of the company’s stock after purchasing an additional 4,192 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in AbbVie were worth $8,810,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Kathmere Capital Management LLC lifted its position in shares of AbbVie by 2.7% during the 2nd quarter. Kathmere Capital Management LLC now owns 3,415 shares of the company’s stock worth $634,000 after buying an additional 91 shares during the period. Cove Private Wealth LLC boosted its stake in AbbVie by 171.0% in the 2nd quarter. Cove Private Wealth LLC now owns 9,911 shares of the company’s stock valued at $1,840,000 after buying an additional 6,254 shares in the last quarter. Finally, Lloyd Advisory Services LLC. grew its position in AbbVie by 27.1% in the second quarter. Lloyd Advisory Services LLC. now owns 1,686 shares of the company’s stock valued at $313,000 after acquiring an additional 360 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Scotiabank started coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. BMO Capital Markets reissued an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday. Finally, Morgan Stanley lifted their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $248.11.

AbbVie Stock Up 0.5%

Shares of NYSE:ABBV opened at $219.21 on Friday. The firm has a market cap of $387.42 billion, a P/E ratio of 166.07, a P/E/G ratio of 0.90 and a beta of 0.36. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company’s 50-day moving average price is $225.60 and its two-hundred day moving average price is $217.41.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the business earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s payout ratio is 524.24%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.